Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | SAT1 | P21673 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17052668 | 0.86 | MEN1 (0.39) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL28396035 | 0.86 | MEN1 (0.50) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL12091537 | 0.86 | MEN1 (0.50) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL20375434 | 0.84 | MEN1 (0.41) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL20370970 | 0.83 | MEN1 (0.36) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL13668048 | 0.80 | MEN1 (0.58) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL22703370 | 0.78 | MEN1 (0.39) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL17309416 | 0.78 | SAT1 (0.33) | SAT1 | |
| SCHEMBL16815000 | 0.78 | SAT1 (0.45) | MEN1KMT2ATSHRCYP3A4SAT1 | |
| SCHEMBL16815001 | 0.78 | SAT1 (0.45) | MEN1KMT2ATSHRCYP3A4SAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-06-30 | — | — | US | disclosed |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | Arrowhead Pharmaceuticals, Inc. (US) | 2022-06-02 | — | — | US | disclosed |
| US-11214802-B2 | RNAi agents for inhibiting expression of alpha-ENaC and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200299691-A1 | RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-09-24 | — | — | US | disclosed |
| EP-2895200-B1 | MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS | TRANSLATE BIO MA INC (US) | 2019-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299691-A1 | RNAi Agents for Inhibiting Expression of Alpha-ENaC And Methods of Use | SCNN1A, SCNN1G, SCNN1B | MEN1 1095/4885KMT2A 1278/4885THRB 1661/4885 |
| US-20220204976-A1 | RNAi Agents for Inhibiting Expression of HIF-2 alpha (EPAS1), Compositions Thereof, and Methods of Use | EPAS1, HIF1AN, HIF1A | MEN1 4217/4885KMT2A 616/4885THRB 397/4885 |
| US-11214802-B2 | RNAi agents for inhibiting expression of alpha-ENaC and methods of use | SCNN1A, SCNN1G, SCNN1B | MEN1 1095/4885KMT2A 1278/4885THRB 1661/4885 |
| US-20220170015-A1 | ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE | SERPINA2, SERPINC1, SERPINA3 | MEN1 1361/4885KMT2A 3675/4885THRB 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.